Daimantas Milonas1, Stasys Auskalnis2, Giedrius Skulcius2, Inga Gudinaviciene3, Mindaugas Jievaltas2, Steven Joniau4. 1. Department of Urology, Lithuanian Health Science University, Eiveniu 2, 50009, Kaunas, Lithuania. daimantas.milonas@kaunoklinikos.lt. 2. Department of Urology, Lithuanian Health Science University, Eiveniu 2, 50009, Kaunas, Lithuania. 3. Department of Pathology, Lithuanian Health Science University, Kaunas, Lithuania. 4. Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Abstract
PURPOSE:High-grade prostatic intraepithelial neoplasia (HGPIN) is a potential precursor of prostate cancer (PCa), and patients with HGPIN are at high risk for PCa development. Objective of our study was to evaluate the efficacy of dutasteride 0.5 mg in PCa prevention among men with isolated HGPIN on biopsy. METHODS: This prospective, randomized, phase III, open-label 3-year trial assessed dutasteride versus active surveillance in patients with HGPIN. Patients were randomized to dutasteride 0.5 mg daily or active surveillance. Per-protocol prostate biopsies were performed at 6, 12, 24, and 36 months until cancer detection or study end. The primary end point was cancer-free survival (CFS). An intention-to-treat analysis was done for patients who underwent at least one per-protocol biopsy. An efficacy analysis was done for patients who completed the study. CFS was evaluated using Kaplan-Meier and log-rank analysis. RESULTS: In total, 220 men were randomized (dutasteride, n = 107; surveillance, n = 113). PCa was detected in 47.6: 49.1 % in the surveillance group and 45.9 % in the treatment group (p = 0.66). The detected PCa differentiation by Gleason score (GS) was GS 6 in 76.9 %, GS 7 in 19.8 %, and GS ≥ 8 in 3.3 %, with no difference between groups. The 3-year PCa-free survival was 43.6 % in the surveillance and 49.6 % in the dutasteride group (log rank p = 0.57). Limitations include a relatively high non-adherence rate, open-label design, and baseline sextant biopsy scheme. CONCLUSIONS:Dutasteride 0.5 mg for 3 years did not lower the PCa detection rate but did not worsen detected PCa characteristics in men with HGPIN.
RCT Entities:
PURPOSE: High-grade prostatic intraepithelial neoplasia (HGPIN) is a potential precursor of prostate cancer (PCa), and patients with HGPIN are at high risk for PCa development. Objective of our study was to evaluate the efficacy of dutasteride 0.5 mg in PCa prevention among men with isolated HGPIN on biopsy. METHODS: This prospective, randomized, phase III, open-label 3-year trial assessed dutasteride versus active surveillance in patients with HGPIN. Patients were randomized to dutasteride 0.5 mg daily or active surveillance. Per-protocol prostate biopsies were performed at 6, 12, 24, and 36 months until cancer detection or study end. The primary end point was cancer-free survival (CFS). An intention-to-treat analysis was done for patients who underwent at least one per-protocol biopsy. An efficacy analysis was done for patients who completed the study. CFS was evaluated using Kaplan-Meier and log-rank analysis. RESULTS: In total, 220 men were randomized (dutasteride, n = 107; surveillance, n = 113). PCa was detected in 47.6: 49.1 % in the surveillance group and 45.9 % in the treatment group (p = 0.66). The detected PCa differentiation by Gleason score (GS) was GS 6 in 76.9 %, GS 7 in 19.8 %, and GS ≥ 8 in 3.3 %, with no difference between groups. The 3-year PCa-free survival was 43.6 % in the surveillance and 49.6 % in the dutasteride group (log rank p = 0.57). Limitations include a relatively high non-adherence rate, open-label design, and baseline sextant biopsy scheme. CONCLUSIONS:Dutasteride 0.5 mg for 3 years did not lower the PCa detection rate but did not worsen detected PCa characteristics in men with HGPIN.
Entities:
Keywords:
Chemoprevention; Dutasteride; High-grade prostatic intraepithelial neoplasia; Prostate cancer
Authors: Neil E Fleshner; M Scott Lucia; Blair Egerdie; Lorne Aaron; Gregg Eure; Indrani Nandy; Libby Black; Roger S Rittmaster Journal: Lancet Date: 2012-01-24 Impact factor: 79.321
Authors: Ashley E Ross; Zhaoyong Feng; Phillip M Pierorazio; Patricia Landis; Patrick C Walsh; H Ballentine Carter; Bruce J Trock; Edward M Schaeffer Journal: BJU Int Date: 2012-01-30 Impact factor: 5.588
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Paolo Gontero; Giancarlo Marra; Francesco Soria; Marco Oderda; Andrea Zitella; Francesca Baratta; Giovanna Chiorino; Ilaria Gregnanin; Lorenzo Daniele; Luigi Cattel; Bruno Frea; Paola Brusa Journal: Prostate Date: 2015-04-20 Impact factor: 4.104
Authors: Neil E Fleshner; Linda Kapusta; Bryan Donnelly; Simon Tanguay; Joseph Chin; Karen Hersey; Anne Farley; Ken Jansz; D Robert Siemens; Kiril Trpkov; Louis Lacombe; Martin Gleave; Dongsheng Tu; Wendy R Parulekar Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Michael Marberger; Stephen J Freedland; Gerald L Andriole; Mark Emberton; Curtis Pettaway; Francesco Montorsi; Claudio Teloken; Roger S Rittmaster; Matthew C Somerville; Ramiro Castro Journal: BJU Int Date: 2011-06-23 Impact factor: 5.588
Authors: Jason Gee; Howard Bailey; Kyungmann Kim; Jill Kolesar; Tom Havighurst; Kendra D Tutsch; William See; Michael B Cohen; Nick Street; Leon Levan; David Jarrard; George Wilding Journal: Prostate Date: 2013-01-17 Impact factor: 4.104
Authors: Levent Trabzonlu; Ibrahim Kulac; Qizhi Zheng; Jessica L Hicks; Michael C Haffner; William G Nelson; Karen S Sfanos; Onur Ertunc; Tamara L Lotan; Christopher M Heaphy; Alan K Meeker; Srinivasan Yegnasubramanian; Angelo M De Marzo Journal: Cold Spring Harb Perspect Med Date: 2019-04-01 Impact factor: 6.915